MTOR and neoplasm: The PI3K/Akt/mTOR pathway, a central regulator of cell survival, metabolism, and therapy resistance, is frequently dysregulated in NPC, driving tumor progression and chemoradiotherapy failure (Teng et al., 2021; Qin et al., 2020; Li et al., 2022; Chen et al., 2020).